Chester County News and Community Website
Trevena, Inc. (Nasdaq: TRVN), headquartered in Chesterbrook, PA, is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a leading pharmaceutical company, has recently unveiled its financial outcomes for the closing quarter of 2023, amidst a pivotal shift in their corporate …
Trevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environment Read More CHESTERBROOK, PA — Pharmaceutical firm Trevena, Inc. (Nasdaq: TRVN) has recently completed two significant financial transactions, raising approximately $4 million in gross proceeds. The Chesterbrook, Pennsylvania-based company announced its successful …
Trevena Inc. Raises $4 Million in Private Stock and Warrant Offerings Read More CHESTERBROOK, PA — Trevena Inc. (NASDAQ: TRVN) has announced that it has secured a national group purchasing agreement with Premier Inc. for its product, OLINVYK. The agreement came into effect …
Trevena Inc. Secures National Group Purchasing Agreement for OLINVYK with Premier Inc. Read More CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …
Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (NASDAQ: TRVN) has reported its Q3 2023 financial results, shedding light on a net loss attributable to common stockholders of $7.9 million, or …
Trevena Reports Promising Q3 2023 Results, Reveals Progress in TRV045 Studies and OLINVYK Sales Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, …
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023 Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) this week reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor …
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced the recent completion of the initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.
Trevena’s Exciting Findings: Insights on OLINVYK’s Impact on Respiratory Health to be Revealed at ASA Conference Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, recently announced receipt of a $15 million tranche under its non-dilutive ex-US royalty-based financing (the R-Bridge Financing). This tranche of funding …
Trevena Secures $15M Non-Dilutive Tranche and Shares Promising Business Update Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, recently announced preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for …
Trevena’s TRV045: Promising Results in Neuropathic Pain Trials with CNS Target Engagement Read More